KIF2C (Kinesin Family Member 2C)

We have established the correlation between the pathogenesis of GC's "cold and heat disorder" and modern pathological indicators (inflammation, oxidative damage, and cell apoptosis disorder) from the perspective of traditional Chinese medicine syndrome, providing a theoretical basis for the clinical application of BXXXD. The online version contains supplementary material available at 10.1007/s10616-025-00888-3.

The results confirmed that the genes were significantly upregulated in tumor lesions. These findings underscore the importance of HCC MPCDS as a prognostic biomarker and highlight its potential for guiding personalized treatment strategies in HCC.

Quantitative reverse transcription polymerase chain reaction (qRT-PCR) analysis confirmed the device's ability to selectively capture mRNA with a high capture efficiency of 93% within 15 minutes and 48% of thermal release efficiency after 10 minutes at 95 °C. By incorporating this optimized approach into a fully automated lab-on-chip system, puromycin-linked mRNAs could be directly used for peptide screening of kinesin family member 2C (KIF2C), a protein overexpressed in aggressive cancers.

This study identifies CDC20 as a key prognostic biomarker for bladder cancer, providing novel insights for early diagnosis, clinical treatment, and prognosis assessment. The findings highlight the potential of CDC20 as a therapeutic target and underscore the value of integrated bioinformatics and experimental validation in biomarker discovery.

The TRS effectively categorizes patients according to their prognosis and reflects immune-related features. KIF2C, identified as a crucial gene within the TRS, could be explored as a potential therapeutic candidate, offering insights into LUAD metabolism and informing the development of metabolism-based therapeutic strategies.

Finally, we confirmed that KIF2C may be the most central MSRRS gene and demonstrated by in vitro experiments that KIF2C could promote G2/M transition in HCC cells by targeting CDK1/CCNB1/PLK1 signaling. The novel MSs and robust MSRRS we identified effectively exposed the heterogeneity of HCC and have the potential to predict prognosis and guide individualized precision therapy.

We integrated lactylation modification profiles with transcriptomic data from three murine liver regeneration datasets (GSE20426, GSE70593, GSE4528)...This work uniquely establishes lactylation as a metabolic-epigenetic bridge linking physiological regenerative pathways to oncogenesis. By leveraging liver regeneration models and machine learning, we propose the identified gene panel as dual-purpose biomarkers for HCC diagnosis and therapeutic targeting, offering new insights into the metabolic-epigenetic regulation of HCC.

Since the compared signal was detected by using an antibody, this suggests that OCTRD14 may behave similarly to antibody-like candidates. Overall, this high-efficiency peptide screening IMS shows promise for future biomedical applications.

This study is the first to define a G2/M-phase gene module promoting CCA progression and map its single-cell dynamics, highlighting CCNB1 as a therapeutic target. Our results reveal SRGs as a coordinated oncogenic network underlying tumor aggressiveness, providing mechanistic insights for future SRG-targeted therapies.

MSN, KIF2C and RFC4 may serve as potential biomarkers for diagnosing and predicting the prognosis of HNSC, providing new insights into targeted therapy.

HROB is upregulated in LUAD and represents a promising prognostic biomarker, driving tumor proliferation, migration, and invasion.

In vivo, subcutaneous intratumoral injection of the miR-4484 mimic in nude mice significantly inhibited HCC tumour growth. These findings highlight miR-4484 as a potential tumour suppressor in HCC through its direct targeting of KIF2C, underscoring its promise as a therapeutic target for HCC treatment.